Immunopathogenesis and Therapies of Granulomatous Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1611

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, Division of Allergy and Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Interests: Granulomatous disease; immune

Special Issue Information

Dear Colleagues,

Granulomatous diseases affect various organs in the body, leading to a wide range of symptoms and complications. A few well-known granulomatous diseases include tuberculosis, sarcoidosis, chronic beryllium disease (CBD), and Crohn’s disease.

These diseases are characterized by the formation of granulomas, which are aggregates of immune cells, particularly macrophages, that form in response to persistent immune stimulation. The immunopathogenesis of granulomatous diseases involves coordinated action of innate, adaptive, and structural cells. However, how the interaction between these immune cells leads to the formation of granulomatous structures is poorly understood. Besides the immune cells, multiple factors involving genetics and environmental exposures are also critical elements involved in granuloma formation.

In this series, we would like to collect the articles that will describe

1) how antigen persistence or hyperreactivity involves continuous activation of immune cells as the immune system is unable to eliminate them. Information about the source of antigen or stimulus involved in granulomatous inflammation is important,
2) how innate molecules and innate immune cells (mononuclear phagocytes) contribute to the pathogenesis of granulomatous diseases,
3) the role of adaptive immune cells in perpetuating granulomatous diseases,
4) the role of genetic predisposition and gender in granulomatous diseases.

The other part of this collection will focus on the therapeutic approaches employed so far to treat or modulate the granulomatous disease. Therapeutic strategies for granulomatous diseases aim to suppress inflammation, modulate immune responses, and target the underlying cause of the disease. Treatment may vary depending on the specific disease and its severity. Some common therapeutic approaches include Anti-inflammatory drugs, immunosuppressive drugs, antimicrobial therapy, and supportive therapy.

Dr. Shaikh Muhammad Atif
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Granulomatous diseases
  • tuberculosis
  • sarcoidosis
  • chronic beryllium disease (CBD)
  • Crohn's disease
  • immune cells
  • genetics
  • environmental exposures;therapeutic approaches

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 2399 KiB  
Article
Imbalance of B-Cell Subpopulations in the Microenvironment of Sarcoidosis or Lung Cancer
by Agata Raniszewska, Iwona Kwiecień, Elżbieta Rutkowska, Joanna Bednarek, Rafał Sokołowski, Piotr Miklusz, Piotr Rzepecki and Karina Jahnz-Różyk
Cells 2024, 13(15), 1274; https://doi.org/10.3390/cells13151274 - 29 Jul 2024
Cited by 1 | Viewed by 1210
Abstract
Although the role of T lymphocytes in sarcoidosis (SA) and lung cancer (LC) is quite well reported, the occurrence of B cells in disease microenvironments may suggest their potential role as natural modifiers of the immune response. The aim of this study was [...] Read more.
Although the role of T lymphocytes in sarcoidosis (SA) and lung cancer (LC) is quite well reported, the occurrence of B cells in disease microenvironments may suggest their potential role as natural modifiers of the immune response. The aim of this study was to investigate the B-cell profile and lymphocyte-related hematological parameters between patients with SA, LC and healthy controls (HCs). The cells were assessed by flow cytometry and a hematological analyzer in peripheral blood (PB) and material from lymph nodes (LNs) obtained by the EBUS/TBNA method. We showed that in SA patients, there were higher percentages of naïve B and CD21low B cells and a lower percentage of class-switched memory B cells than LC patients in LNs. We observed a higher median proportion of non-switched memory and transitional B cells in the PB of SA patients than in LC patients. We noticed the lowest median proportion of class-switched memory B cells in the PB from SA patients. LC patients had a higher percentage of RE-LYMP and AS-LYMP than SA patients. Our study presented a different profile of B-cell subpopulations in SA and LC patients, distinguishing dominant subpopulations, and showed the relocation from distant compartments of the circulation to the disease microenvironment, thus emphasizing their role. Full article
(This article belongs to the Special Issue Immunopathogenesis and Therapies of Granulomatous Diseases)
Show Figures

Figure 1

Back to TopTop